For a patient with systemic lupus erythematosus (photosensitivity, malar rash, arthritis) and lupus nephritis, positive anti‑double‑stranded DNA antibodies, and hypertension (blood pressure 155/90 mmHg), what is the next best step: reassure, start steroids, control blood pressure, or obtain a renal biopsy?

Best Next Step: Renal Biopsy

The best next step is to obtain a renal biopsy (Option D) to guide immunosuppressive treatment decisions, while simultaneously initiating blood pressure control. This patient has clinical evidence of active lupus nephritis requiring histological classification before definitive therapy can be optimally selected.

Rationale for Renal Biopsy Priority

The most recent and authoritative guidelines universally emphasize that immunosuppressive treatment decisions must be guided by renal biopsy findings 1. The EULAR/ERA-EDTA 2012 recommendations explicitly state that "any sign of renal involvement—in particular, urinary findings such as reproducible proteinuria ≥0.5 g/24 h especially with glomerular haematuria and/or cellular casts—should be an indication for renal biopsy. Renal biopsy is indispensable since in most cases, clinical, serological or laboratory tests cannot accurately predict renal biopsy findings" 1.

Why Biopsy Before Treatment

• Class-specific therapy: Treatment intensity varies dramatically based on ISN/RPS classification. Class III/IV requires aggressive immunosuppression (mycophenolate or cyclophosphamide plus steroids), while Class II may not require immunosuppression at all 2
• Cannot predict histology: Even with positive anti-dsDNA antibodies, clinical and serological findings cannot reliably predict the specific histological class or degree of activity versus chronicity 1
• Chronicity assessment: The biopsy reveals the extent of irreversible damage (chronicity index), which affects treatment decisions and prognosis 2

Concurrent Blood Pressure Management

While biopsy is the diagnostic priority, blood pressure control should be initiated immediately and is not mutually exclusive 3. At 155/90 mmHg, this patient has stage 1 hypertension that requires treatment:

• Target BP in lupus nephritis: <130/80 mmHg 4
• First-line agents: ACE inhibitors or ARBs are preferred as they provide both antihypertensive and antiproteinuric effects 3, 4
• Cardiovascular risk: SLE patients with nephritis are at high cardiovascular risk, making BP control essential for long-term outcomes 5, 4

Why Not the Other Options

Reassurance (Option A) - Inappropriate

This patient has active lupus nephritis with positive anti-dsDNA antibodies and hypertension. Reassurance would be negligent and could lead to irreversible renal damage and progression to end-stage renal disease 3.

Steroids Alone (Option B) - Premature

Starting steroids without biopsy confirmation is problematic because:

• Treatment regimen depends on histological class (Class II vs III/IV vs V require different approaches) 1, 2
• Steroids alone are insufficient for proliferative nephritis—combination with immunosuppressives (mycophenolate or cyclophosphamide) is required 1
• You may under-treat or over-treat without knowing the specific pathology

BP Control Alone (Option C) - Insufficient

While BP control is necessary, it is inadequate as monotherapy for active lupus nephritis. The underlying immune-mediated glomerular injury requires immunosuppression to prevent progression to chronic kidney disease 3, 1.

Clinical Algorithm

Immediate actions (within days):

1. Arrange urgent renal biopsy (unless contraindicated by bleeding risk)
2. Start ACE inhibitor or ARB for BP control targeting <130/80 mmHg
3. Initiate hydroxychloroquine if not already on it (recommended for all SLE patients) 2, 1
4. Assess for additional baseline labs: complete metabolic panel, urinalysis with microscopy, 24-hour urine protein or spot urine protein-to-creatinine ratio, complement levels (C3, C4)

Post-biopsy (within 1-2 weeks):

• Class III/IV (proliferative): Mycophenolate mofetil (target 3 g/day) OR low-dose IV cyclophosphamide PLUS glucocorticoids (IV methylprednisolone pulses followed by oral prednisone 0.5 mg/kg/day, tapering to ≤10 mg/day by 4-6 months) 1
• Class V (membranous) with nephrotic-range proteinuria: Mycophenolate plus oral prednisone 1
• Class II: Usually no immunosuppression needed 2

Common Pitfalls to Avoid

1. Delaying biopsy: Waiting to see if symptoms improve delays appropriate treatment and risks irreversible damage
2. Treating based on serology alone: Anti-dsDNA positivity indicates lupus activity but doesn't specify the histological class or guide treatment intensity
3. Ignoring BP: Even while arranging biopsy, BP control should begin immediately as hypertension accelerates renal damage 5, 6
4. Starting high-dose steroids empirically: This may mask disease activity and complicate interpretation of treatment response without addressing the underlying pathology appropriately

The 2024 KDIGO guidelines 7 and 2020 EULAR/ERA-EDTA update 8 continue to emphasize that biopsy-guided treatment optimization leads to better long-term renal outcomes and quality of life.